Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 2/20 | 0.48 |
| ▸ | MARK3 | P27448 | 6/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | SGK1 | O00141 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12418680 | 0.92 | MARK3 (0.54) | MARK3ROCK2ROCK1MAPK1EGFR | |
| SCHEMBL2288466 | 0.86 | GAK (0.43) | MARK3ALDH1A1ROCK2ROCK1MAPK1 | |
| SCHEMBL12379632 | 0.84 | GAK (0.43) | MARK3ALDH1A1JAK2JAK1TYK2 | |
| SCHEMBL2291469 | 0.83 | MARK3 (0.59) | MMP12MARK3ROCK2ROCK1MAPK1 | |
| SCHEMBL12379636 | 0.83 | MARK3 (0.46) | MMP12MARK3ROCK2ROCK1MAPK1 | |
| SCHEMBL12419199 | 0.79 | MARK3 (0.59) | MARK3ROCK2ROCK1MAPK1EGFR | |
| SCHEMBL12379630 | 0.79 | MARK3 (0.59) | MARK3ROCK2ROCK1MAPK1EGFR | |
| SCHEMBL1907482 | 0.78 | RET (0.49) | SMN1; SMN2ROCK2ROCK1MAPK1EGFR | |
| SCHEMBL13509541 | 0.77 | ROCK2 (0.62) | ROCK2ROCK1 | |
| SCHEMBL12379637 | 0.77 | MARK3 (0.54) | MARK3ROCK2ROCK1MAPK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195933-A1 | PYRAZOLO[1,5-A]PYRIDINES AS MARK INHIBITORS | MARK3, MARK4, MARK1 | MMP12 4120/4885MARK3 1/4885HPGD 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.